You reached goal weight on a GLP-1, and the scale finally shows the number you set when you started. It does not tell you what to do next. You could keep the dose where it is, step it down or stop altogether. Each of those is a decision, and the next refill will make one of them for you if nobody else does. Behind all three sits the question you may not have said out loud: what happens if the weight starts to come back and nobody is watching.
So the objection is reasonable. If what you want is the prescription, and you already have one, why would you pay a membership for it? This piece answers that for one situation: yours, at goal weight, with a refill on the calendar. It explains what the decision at goal involves, why the way your prescriber gets paid bears on it, what GoodLife Health costs and does, and who should not join.
- At goal weight, the next refill is a dose decision, and it deserves your labs as well as your weight.
- The trials report average loss over 68 and 72 weeks; they cannot tell you what your body will do after your goal.
- A company paid on the medicine can earn less if your dose falls or stops; one paid a flat fee earns the same at any dose.
- GoodLife Health is $299 a month, $598 at sign-up for the first two months, with quarterly panels and a clinician who stays.
- Medication goes to the pharmacy you choose at that pharmacy's price, and GoodLife Health takes nothing on it.
- This is not for anyone who wants only a refill, a compounded supply or a promise about the scale.
You reached the number, and nobody asked about the next one
Think back over how you got here. If your prescription came from an online program, the system around it was built for the climb. The messages were about the next dose and the next fill, with a short form now and then asking how you were tolerating it. That system did what it was designed to do, and you lost the weight. Then you arrived at goal, and the messages did not change, because nothing in that design was waiting for you to arrive.
What you have at this point is a prescription, a dose and a weight. What you may not have is a set of labs from before you started, a set from now, and a person who has read both. If a panel was drawn at the beginning, it may sit in a portal you no longer open. If none was drawn, the only record of what the medication did is your scale.
The questions you have are specific. Should the dose stay where it is to hold the weight, or come down? If it comes down, by how much, and what would tell anyone that it came down too far? If you stop, what should be measured, and when, so that a rise is caught as a number in a report rather than noticed as a tighter waistband? And what did the loss do to the rest of you: your blood sugar, your lipids, your liver enzymes, the markers that never show up on a scale? A refill answers none of these.
Price is on your mind too, because at goal the medication stops being a project with an end date and becomes a long-term line item. If you started on a compounded copy during the shortage, as millions of people did, legally, you may already have moved to the branded product at a higher price, or you may be wondering whether a cheaper compounded supply for maintenance still exists. And you already have a prescriber, which is the third reason a membership looks redundant. You are right to ask what it would add.
What is actually going on at goal weight
The trials measured the loss
The two medicines most people take were tested in large, published trials. In STEP 1, 1,961 adults on semaglutide 2.4 mg lost an average of 14.9% of their body weight over 68 weeks. In SURMOUNT-1, 2,539 adults on tirzepatide 15 mg lost an average of 20.9% over 72 weeks. Some people lost more and some less, and the trials excluded many common conditions. They are strong evidence that the medicines work on the way down. They are averages across thousands of people, and they cannot tell you what your own body will do after your own goal. We do not know that either, and nobody can tell you from your weight alone.
The decision rests on things a refill does not collect
What a clinician needs at goal is the material the decision rests on: how long you have been on the medication, at what dose, what you tolerated, your history and your labs. Before GLP-1 therapy starts, a metabolic panel of fasting glucose, HbA1c, a lipid panel and liver enzymes is standard, and our guide to what a direct primary care membership includes gives the reason plainly: a protocol built without labs is a guess. The same holds for a protocol that changes at goal. If you had a panel at the start, today's panel can be read against it. If you did not, the first panel drawn now becomes the baseline that every later one is compared with, and that alone is worth having before the dose moves.
The way your prescriber is paid shapes the answer
The second thing going on is less comfortable. Our plain-language white paper on how GLP-1 telehealth companies make money sets out the three ways a company gets paid when it prescribes a GLP-1: a margin on the medicine, a low membership fee plus billing your insurance, or one flat fee with the medicine sold at the pharmacy's own price. As that paper puts it, the way a company gets paid is the pressure its clinicians work under. It does not make anyone good or bad. It decides what the company is rewarded for.
At goal weight, that pressure becomes concrete. Under a margin on the medicine, a lower dose or a stop can mean lost revenue, and continuing at the current dose is the outcome the business is built around. A clinician inside that model can still make the right call; the model simply does not pay them to. Under a flat fee, the dose can go up, down or to nothing, and the company earns exactly the same. That is the integrity argument for a membership, and it is the whole of it.
At goal weight, what you need from a prescriber is a decision about the dose, made with your numbers by someone who earns the same whatever the answer.
The medication is becoming a published price
The field is moving in the same direction. Both manufacturers now sell branded medication directly to self-pay patients. As published in September 2026, NovoCare lists Wegovy pens at $199 a month for the first two fills, an introductory offer for new patients through December 2026, and $349 a month after, with the Wegovy pill from $149 a month at lower doses. LillyDirect lists Zepbound vials at $299 to $449 a month depending on dose.
Mass-market compounding, meanwhile, has ended. The FDA declared the semaglutide shortage resolved on February 21, 2025, and the last grace period, for outsourcing facilities, closed on May 22, 2025. A narrow exception remains for a specific patient with a documented clinical need the branded product cannot meet, and the FDA has published its concerns about unapproved GLP-1 drugs used for weight loss. Both manufacturers have sued companies selling compounded versions. Lilly has said it plans to file retatrutide for FDA approval in the first quarter of 2027; it is not approved today.
Taken together, those dated facts point one way. The medicine is turning into a known price at a known pharmacy, and the list of options is getting longer. What stays scarce is the judgment about which medicine, at which dose, for how long, read against your own numbers.
The three objections, answered
"I can get the prescription for $99 online." You can, and this piece will not argue with that price. What matters at goal is what the fee is set up to pay for when you need a decision about the dose rather than another fill. "Why pay a membership when the drug is the expensive part?" Because the drug is the expensive part. That is exactly why the person deciding your dose should earn nothing on it, and why it should be bought at the pharmacy's own price. "I already have a prescriber." Then ask them the questions in the last section of this piece. If the answers come with labs and a plan, you may not need us.
What the membership does at goal, and what it costs
How you get in
The path has four steps: the eligibility check, the intake, the checkout, then a clinician's review. Not everyone is accepted. The clinician reads your history, your current medication and dose, and what you are trying to decide, and then accepts you into care or does not.
What it does
Once you are accepted, you have four cardiometabolic lab panels a year, one each quarter, with every result in your hands. A clinician reads them with you, by video visit and through asynchronous messaging with the care team, and that clinician stays; GoodLife Health's clinicians are licensed in all fifty states. The decision at goal, whether to hold, lower or stop, is made with those numbers and revisited when the next panel comes back. When a medication is clinically indicated, it is prescribed to the pharmacy you choose at that pharmacy's own price: branded, FDA-approved medication such as Wegovy, Zepbound, Mounjaro or Ozempic. GoodLife Health sets nothing, sees nothing and takes nothing on medication. The fee is the same whatever medication is indicated and whatever the dose, with no molecule upcharge and no dose upcharge, so a lower dose changes nothing about what you pay us.
GoodLife Health sits between the $20,000-a-year concierge practice and the $99-a-month compounded app, and it is more expensive than most memberships. We say so because the price should be the first thing you know.
What it does not do
It does not promise that the weight stays off. No one at GoodLife Health will tell you what you will weigh in a year. It does not prescribe compounded GLP-1, for maintenance or for anything else. It does not promise that insurance will cover your medication; that is between you, your plan and the pharmacy, and prior authorization is the pharmacy's process, which we do not run, speed or win. It does not replace your insurance. The membership pairs with insurance for catastrophic coverage and replaces the primary-care relationship.
Whether to hold, lower or stop a GLP-1 at goal weight is a clinician's decision, made with your history and your labs. A dose decision built without labs is a guess.
What it returns
What you get back is the diagnosis a refill never produced: what the loss did to your metabolic markers, read against where they started. You get those markers followed over time, so that a change shows up as a number in the next panel instead of a surprise. And you do not repeat the eight-minute visit, the one that ends with a renewal and no plan. This is precision direct primary care for cardiometabolic optimization: test first, treat second, and sell neither the drug nor the dose.
Before the next refill: what to do this week
Whether or not you join, these steps are worth taking before the next fill, and they cost nothing.
- Write down your start date, your starting weight, every dose you have taken and for how long, and any side effects. Any clinician will ask for this.
- Find the labs drawn before you started, if there were any. Request them from the program or the lab if they are not already in your hands.
- Ask your current prescriber three questions: which labs they want before the dose changes, what the plan is if your weight rises, and whom you message if it does.
- Check the current self-pay price for your medication on the manufacturer's own page, and note the date, because those prices move. The NovoCare introductory offer for new patients runs through December 2026.
If the answer to the third question is labs, a plan and a name, you already have what this membership sells, and you should keep it. If the answer is the next refill, you know what is missing.
As for timing, the next refill is when the dose decision gets made, on purpose or by default. A panel drawn before the dose moves gives every later panel something to be compared with. That window is open now, and it closes the day the dose changes without one.
Who this is not for
If all you want is the refill, at the lowest monthly figure, with no labs and no clinician reading them, this is not for you, and a $99 prescription will suit you better. If you want a compounded supply, we do not prescribe it. If you want a guarantee about the scale, nobody here will give you one. If your current prescriber already orders labs, reads them with you and has a plan for maintenance, keep that prescriber. And if you live outside the fifty states, we cannot see you. The membership is for a patient who wants the decision at goal made with numbers, by someone who earns the same whatever the answer.
The membership is $299 a month, month to month, with $598 charged at sign-up for the first two months. If the clinician cannot accept you into care, the $598 is refunded in full; once you are accepted, the first two months are non-refundable, and medication billed by a pharmacy follows that pharmacy's own return and refund policy. The fee buys four cardiometabolic panels a year, every result in your hands, messaging and video visits, and a clinician who stays. Medication is prescribed to your pharmacy at that pharmacy's price, and we take nothing on it. The fee is generally eligible for HSA or FSA pre-tax dollars. What makes it different is that we test first, treat second and sell neither the drug nor the dose. If your next refill is coming and nobody has drawn a panel, that is your reason to start now.
Related Reading
- How GLP-1 Telehealth Companies Make Money: A Plain-Language Whitepaper
- What Does a Direct Primary Care Membership Include in 2026
References
- NovoCare Pharmacy — Wegovy self-pay pricing (Novo Nordisk). 2026. www.novocare.com/pharmacy/wegovy.html
- Zepbound Self Pay Journey Program — LillyDirect vial pricing (Eli Lilly). 2026. zepbound.lilly.com/savings
- FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (U.S. Food and Drug Administration). 2025. www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
- Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). 2021. pubmed.ncbi.nlm.nih.gov/33567185/
- Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). 2022. pubmed.ncbi.nlm.nih.gov/35658024/